'%2F%3E%3Cpath%20d%3D'M11%205H21M13.5%205V11.6A8.5%208.5%200%201%200%2018.5%2011.6V5'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'3.4'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Cpath%20d%3D'M10.6%2019.6L13.9%2021.8L17.6%2018.4L21.4%2020.4'%20fill%3D'none'%20stroke%3D'%23fff'%20stroke-width%3D'2.6'%20stroke-linecap%3D'round'%20stroke-linejoin%3D'round'%2F%3E%3Ccircle%20cx%3D'17.6'%20cy%3D'18.4'%20r%3D'2.6'%20fill%3D'%23fff'%2F%3E%3C%2Fsvg%3E){kind=small}
Amrutanjan Health Care Limited
AMRUTANJAN (NSE) · AMRUTANJAN (BSE 590006) · ISIN INE098F01031 · Pharmaceuticals · Est. 1936 · listed 2015 · website
Not on any surveillance list
In Q1 FY27 (quarter to 30 June 2026, standalone), revenue was ₹102.97 cr and profit after tax ₹4.37 cr. Revenue was 9.5% higher than in Q1 FY26.
Open the full company file Every section, filings and your notes, in the app.
Quarterly results
| Quarter | Revenue | Profit after tax | EPS (₹) | Filed |
|---|---|---|---|---|
| Q1 FY27 standalone | ₹102.97 cr | ₹4.37 cr | 1.51 | 11 Aug 2026 |
| Q4 FY26 standalone | ₹149.77 cr | ₹16.19 cr | 5.60 | 8 May 2026 |
| Q3 FY26 standalone | ₹141.04 cr | ₹19.45 cr | 6.73 | 3 Feb 2026 |
| Q2 FY26 standalone | ₹117.7 cr | ₹13.96 cr | 4.83 | 10 Nov 2025 |
| Q1 FY26 standalone | ₹94.05 cr | ₹8.31 cr | 2.87 | 12 Aug 2025 |
| Q3 FY25 standalone | ₹316.4 cr | ₹35.66 cr | 12.33 | 12 Feb 2025 |
| Q2 FY25 standalone | ₹193.65 cr | ₹16.41 cr | 5.68 | 12 Nov 2024 |
| Q1 FY25 standalone | ₹83.74 cr | ₹4.62 cr | 1.60 | 13 Aug 2024 |
Balance sheet
| As of | Total equity | Borrowings | Total assets |
|---|---|---|---|
| 31 Mar 2026 standalone | ₹370.23 cr | ₹0 cr | ₹508.89 cr |
| 30 Sep 2025 standalone | ₹342.07 cr | ₹0 cr | ₹432.36 cr |
| 31 Mar 2025 standalone | ₹326.61 cr | ₹0 cr | ₹421.39 cr |
Shareholding
| Promoter | FII | DII | Public |
|---|---|---|---|
| 46.52% | 3.47% | 6.90% | 53.45% |
Latest filings
- Annual Report FY2025-26 (New) 6 October 2026 · NSE
- Amrutanjan Health Care Limited has informed the Exchange about Investor Presentation 12 August 2026 · NSE
- Amrutanjan Health Care Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026. 11 August 2026 · NSE
- Nageswaramma Private Trust has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Reg 15 June 2026 · NSE
- Amulya Kamakshi Priya Arikirevula has Submitted to the Exchange a copy of Disclosure under Regulation 31(4) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeove 15 June 2026 · NSE
Other companies in Pharmaceuticals
- Lupin Limited
- Sun Pharmaceutical Industries Limited
- Cipla Limited
- Dr. Reddy's Laboratories Limited
- Torrent Pharmaceuticals Limited
- Zydus Lifesciences Limited
- Aurobindo Pharma Limited
- Divi's Laboratories Limited
Figures as filed by the company with NSE and BSE; surveillance status from the exchanges' lists. Updated 6 October 2026.
Information and calculation tools by Rachid Asen. Not investment advice or research. Facts from company filings and the exchanges' lists, for information only; not a recommendation to buy, sell or hold. Verify with the exchange.